Crossing above two lines of potential support in its 50-Day Simple Moving Average (SMA) and its 13-Day Exponential Moving Average (EMA).
And now with those 2 lines potentially building further support, we could see a squeeze help return this profile back up to an area around its 200-Day SMA of $1.78.
Ready for the name and symbol? Today's breakout Nasdaq idea is:
*SeqLL Inc. (SQL)*
SeqLL was founded in 2013 to bring a new breed of next generation sequencing (NGS) technology, True Single Molecule Sequencing (tSMS), to the research and healthcare communities.
And on top of that eye-popping, potential-filled chart above, there is one key reason to pay close attention to SQL today...
SQL Has A Tiny Float!
According to the Yahoo Finance website, SQL has a low float.
The website reports this profile to have approximately 4.95Mn shares in its float.
Why is that important? It's important on one crucial level. Volatility.
With so few shares available for trading, other potential catalysts (like big news) could spark a vertical move in the short-term.
That's Not All - Big SQL News From June
SeqLL’s Single-Molecule Nucleosome Imaging Method Published in Peer Reviewed Cell Reports Journal
BILLERICA, Mass., June 13, 2022 (GLOBE NEWSWIRE) -- SeqLL Inc. (“SeqLL” or the “Company”) (NASDAQ: SQL; SQLLW), ..., today announced a new study utilizing its single-molecule epigenetic profiling technology was published in the peer-reviewed journal Cell Reports.
The paper, entitled: “H3-K27M-mutant nucleosomes interact with MLL1 to shape the glioma epigenetic landscape,” applied SeqLL developed single-molecule imaging methods to look at cell mutations associated with pediatric brain cancers. The publication’s lead authors, Noa Furth, PhD and Danielle Algranati, MSc, work in Dr. Efrat Shema’s Laboratory in the Department of Immunology and Regenerative Biology at the Weizmann Institute of Science. The single-nucleosome imaging platform allowed researchers to count and decode single modified nucleosomes, providing researchers with a much deeper understanding of how certain cell mutations affect and interact with glioma cells, a type of tumor that occurs in the brain of children. The learnings from this research revealed functional mechanisms through which tumorigenesis occurs, a major component to the field of epigenetics that could lead to revolutionary developments in the vast field of genomics and the possibly other “omics” fields.
“We were thrilled to see the Shema Lab apply this technology to deepen the understanding of cancer on the cellular level. This research explored post translational modifications and the ramifications of specific marks at a level that had not been previously accomplished,” said Daniel Jones, CEO of SeqLL and co-author on the publication. “The study highlights the utility our tools have in the development of new epigenetic-based approaches. We are excited to be part of this groundbreaking work and hopeful that the knowledge gained through our technology will lead to meaningful breakthroughs in the understanding and treatment of various cancers.”
This research builds upon the 2016 Science publication “Single-molecule decoding of combinatorially modified nucleosomes,” led by the laboratory of Dr. Bradley Bernstein.
Read the full article here.
Coverage is officially initiated on SQL. When time permits, do this later: